Topic Listing for Amylin Pharmaceuticals

Ability Generate Revenues Diminished Fail Obtain Acceptable Prices Ac2592 Glp-1
Acceleration Exercisability Vesting Acceleration Extension Options
Acceleration Maturity Rescission Annulment Acceleration Vesting
Acceptance Appointment Successor Acceptance Product
Acceptance Rejection Access Facility Lilly
Account Statements Accounting Costs Computer Software Developed Obtained Internal
Accounting Stock Issued Employees Accounting Stock-based Compensation
Accounting Tax Considerations Accounting Terms Not Otherwise Defined Herein Meanings Assigned
Accounts Accounts Payable Accrued Expenses Other Current Liabilities
Accounts Receivable Acquiring Person
Action Administrator Activities Involve Hazardous Materials Subject Regulation Related Costs
Acts Holders Notes Actual Component Manufacturing Cost
Actual Manufacturing Cost Actual Manufacturing Costs
Actually Joined Eli Lilly Vince His Counterpart Enrique Adams
Addendum Co-promotion Agreement Addition Evidence C-cell Cancers Seen Exposure Primates Studies
Additional Information Find Additional Interest
Additional Questions Sorry Address Plan Sponsor Administrator
Adjustment Accounts Adjustment Investment Experience
Adjustment Provisions Adjustments Changes Securities Corporate Transactions
Adjustments Changes Stock Administration
Administration Board Administrative Agent
Administrative Agent Appointed Attorney-in-fact Administrative Agent Such Sub-agent Issuer Connection Capacity Obligations
Admit Point View Prefer Them Take Time Review Advance
Advance Period Adverse Events
Affiliate Agent Service Legal Process
Aggregate Basket Amount Aggregate Share Cap
Agreement Agreement Not Participate Competitors
Alliance Manager Alliance Managers
Allocation Global Costs Operating Profit Loss Allocation Ous Development Commercialization Costs
Allocation Ous Revenues Alternative Delivery System
Altman Amend
Amended Restated Commercial Supply Agreement Amendment
Amendment Collaboration Agreement Amendment Commercial Supply Agreement
Amendment Consent Waiver Amendment Development License Agreement
Amendment Effective 2009 Amended Restated Supply Agreement 2008 Amendment Effective Date
Amendment Employer Amendment Employment Agreement
Amendment Options Amendment Plan
Amendment Plan Sponsor Amendment Plan Stock Awards
Amendment Prior Agreement Amendment Rights Agreement
Amendment Stock Awards Amendment Supply Agreement
Amendment Waiver Amendments
Amendments Articles Incorporation Bylaws Change Amendments Etc Additional Grantors Successors Assigns
Amendments Registrants Code Ethics Waiver Provision Amendments Waivers
Amgen Agreement Amln 2009 Amylin Pharmaceuticals Inc Earnings Conference Call
Amount Benefits Amount Deferral
Amylin Amylin Co-commercialization Option
Amylin Issues Statement Regarding Open Letter Icahn Amylin Issues Statement Response Carl Icahn
Amylin Know-how Amylin Licensed Compound
Amylin Lilly Amylin Lilly Alkermes
Amylin Lilly Alliance Restructures Exenatide Operations Team Co-locate Amylin Meetings
Amylin Patents Amylin Patents Effective Date
Amylin Path Profitability Amylin Pharmaceuticals
Amylin Pharmaceuticals Announces Appointment Daniel Bradbury Chief Executive Amylin Pharmaceuticals Announces Byetta Revenue
Amylin Pharmaceuticals Biopharmaceutical Committed Improving Lives Through Discovery Amylin Pharmaceuticals Comments Shareholder 13-d Filing
Amylin Pharmaceuticals Confirms Receipt Director Nomination Notices Amylin Pharmaceuticals Elects Adrian Adams Board Directors
Amylin Pharmaceuticals Elects Teresa Beck Board Directors Amylin Pharmaceuticals Inc
Amylin Pharmaceuticals Inc 2001 Non-qualified Deferred Compensation Plan Amylin Pharmaceuticals Inc 2003 Non-employee Directors Stock Option
Amylin Pharmaceuticals Inc 9360 Towne Centre San Diego Amylin Pharmaceuticals Inc Announces Conversion Outstanding 225 Convertible
Amylin Pharmaceuticals Inc Announces Details Redemption 225 Convertible Amylin Pharmaceuticals Inc Announces Offering Convertible Senior Notes
Amylin Pharmaceuticals Inc Announces Pricing Convertible Senior Notes Amylin Pharmaceuticals Reports 2005 Financial Results
Amylin Pharmaceuticals Reports 2006 Financial Results Amylin Pharmaceuticals Reports 2007 Financial Results
Amylin Pharmaceuticals Reports 2009 Financial Results Amylin Pharmaceuticals Reports Financial Results
Amylin Responds Eastbourne Letter Amylin Right Nominees Lead
Amylin Taken Steps Necessary Position Achieve Significant Growth Amylin Urges Shareholders Support Nominees
Amylins Slate Best Qualified Unlock Long-term Value Amylins Unique Approach Obesity Research Development
Analog Analogs Metreleptin
Annex Annex Assignment Assumption
Announced Few Ago Conducted Meta-analysis Primary Cardiovascular Events Annual Cash Bonus
Annual Grant Annual Grants
Annual Meeting Results Annual Meeting Stockholders
Annual Obligation Annual Option Grants
Answer Question Yes Named Underwriter Prospectus Relating Registrable Answer Yes Question Below
Anti-assignment Appendices Exhibits Schedules Certificates
Applicable Conversion Rate Time Prior Close Business Scheduled Applicable Law
Applicable Laws Application Critical Accounting Policies
Application Internal Revenue Code 409a Application Money Collected
Application Proceeds Applications Benefits Inquiries
Appointment Authenticating Agent Appropriate
Approval Amendment 2001 Employee Stock Purchase Plan Approval Amendment 2001 Equity Incentive Plan
Approval Increase Number Authorized Shares Common Stock Approved Investments
Approved List Short-term Investments Arbitration
Areas Focus 2009 Provide Opportunity Create Significant Value Asserting Nominees Better Qualified Boards
Asset Sale Merger Consolidation Reverse Asset-backed Securities
Assignment Assignment Binding Effect
Assignment Delegation Assistance
Associated Exenatide Analysis Was Done Manner Consistent Food At-will Employment
Attachment Attacking Relationship Partner Eli Lilly
Attention Audit
Audit Committee Audit Rights
Audit Safety Applicable Laws Audits
Authorized Disclosure Authorized Within Discretion Rights Powers Conferred Indenture
Automatic Termination Availability Shares
Available Options Available Stock Awards
B-1 Bachem Inc
Background Executives Not Listed Above Bank America
Bankruptcy Laws Baron
Base Salary Basis Presentation
Batch Batch Record
Beck Before Turning Back Dan Let Emphasize Finalize Remaining
Began Selling Marketing Distributing Products Byetta Symlin 2005 Believe Implementation Exenatideone Resolution Pending Regulatory Issues Strong
Benchmarking Beneficial Owner Shares Registered Name Broker Bank Other
Beneficial Ownership Reporting Compliance Benefit Plans
Benefits Benefits Indenture
Better Target Diabetes Market Bid Product
Bid Products Binding Budget
Binding Effect Blackout Provisions Respect Designated Shares
Board Directors Put Forward Slate Highly-qualified Nominees Board Directors Recommends Vote Nominees Director Listed Below
Board Directors Stockholders Board Directors Stockholders Amylin Pharmaceuticals Inc
Boards Leadership Amylin Successfully Executing Stated Strategy Achieving Bonus Payment
Bradbury Broadly Available Road Show
Brokerage Bryson
Budget Long Range Plan Budget Summary
Budget Summary Business Plan Updates Business
Business Overview Business Substantial Risk Product Liability Claims Insurance Expensive
Business Substantial Risk Product Liability Claims Insurance Not Byetta
Byetta Development Activities Byetta Exenatide Injection
Byetta Exenatide Once Weekly Not Being Discussed Upcoming Byetta Manufacturing
Calculation Development Costs Calculations Respect Notes
Cancellation Cancellation Converted Notes
Cancellation Fee Cancellation Re-grant
Cancellation Re-grant Options Capitalization Adjustments
Capitalization Changes Carcinogenicity Studies Liraglutide Was Associated Increased Malignant C-cell
Cardiovascular Disease Cartridge Supply Agreement
Cash Equivalents Cashouts Amounts Not Exceeding Stated Limit
Cause Cautionary Factors Affect Future Results
Certain Covenants Certain Reductions
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certain Rights Trustee Certain Transactions
Certainly Things Looking Whether Not Change Philosophy Havent Certificate Analysis
Certification Certifications
Cessation Resumption Participation Following Change Status Cfr Sections 20080 24024b-2
Cgcp Cglp
Cgmp Change Accounting Policy
Change Control Change Control Distributions
Change Control Severance Payments Change Effective Control Corporation
Change Ownership Corporation Change Ownership Substantial Portion Corporations Assets
Change Place Currency Payment Principal Interest Extension Fee Change Specifications Manufacturing Process
Change Vote After Submitting Proxy Changes Internal Control Over Financial Reporting
Changes Result Over Reduction 2009 Cash Expenditures Changes Result Sales Force Reduction Approximately Annual Gaap
Chief Executive Officer Compensation Chief Financial Officer
Choice Law Claim
Claims Review Procedures Clawback Provision
Clinical Obesity Study Clinical Trial
Closing Location Co-commercialization Agreement Terms
Co-commercialization Expenses Co-promotion Start Date
Cobra Premium Benefits Code Business Conduct Ethics
Collaboration Agreement Collaboration Alkermes Inc
Collaboration Eli Lilly Collaboration Takeda Pharmaceutical Ltd
Collaborative Activities Collaborative Agreements
Collaborative Profit Sharing Collaborative Profit-sharing
Collection Indebtedness Suits Enforcement Trustee Commercial Milestones Products
Commercial Sale Commercial Supply Agreement
Commercial Supply Agreement Pramlintide Commercial Viability
Commercialization Commercialization Activities
Commercialization Costs Commercialization Plan
Commercialization Right Commercially Reasonable Efforts
Commitments Credit Extensions Committee
Committee Composition Common Stock Publicly Traded Common Stock 001 Par Value
Communication Being Distributed Solely Qualified Institutional Buyers Defined Communication Holders
Communication Participants Comparator Studies Exenatide Once Weekly Demonstrated Greater Glucose-lowering
Compared Same Period 2008 Comparison Cumulative Total Return
Compensation Compensation Committee Interlocks Insider Participation
Compensation Human Resources Committee Compensation Mix Measurement
Compensation Philosophy Compensation Program Objectives Philosophy
Compensation Reimbursement Competition
Competition Biotechnology Pharmaceutical Industries Result Competing Products Superior Complaints Adverse Reaction
Compliance Compliance Law
Compliance Laws Compliance Quality Agreement Applicable Laws
Complimentary Parking Please Place Pass Dashboard Car Entering Component Purchase Price
Components Composition
Comprehensive Income Loss Comprehensive Loss
Computation Interest Computer Software Costs Internal
Concentrations Risk Conclusion Regarding Effectiveness Disclosure Controls Procedures
Conditions Receipt Benefits Conduct Regulatory Activities
Conference Call Confident Five-point Plan Put Place Create Value Revolves
Confidential Information Confidential Treatment Request
Confidentiality Conflicting Interests
Conformity Trust Indenture Act Consent Independent Registered Public Accounting Firm
Consideration Consolidate Etc Only Certain Terms
Consolidation Construction
Constructive Termination Consultant
Consultants Contact
Contacts Contaminant
Contemplated Amendments Continue Work Collaborator Eli Lilly Improve Effectiveness Efficiency
Continuing Obligations Continuing Security Interest Transfer Credit Extensions
Continuous Service Contrast Icahn Eastbourne Nominees
Contribution Control
Control Controls Control Holders
Controls Procedures Conversion Privilege Rate
Convertible Senior Notes Cook
Cooperation Cooperation Collaboration Partner
Cordially Invited Attend Meeting Person Whether Not Expect Corporate
Corporate Action Binding Effect Corporate Governance Committee
Corporate Seal Corporate Tax Deduction Compensation Excess
Corporate Trustee Required Eligibility Corporateplan Retirement Executive Basic Plan Document
Corrections Cory Kasimov Jpmorgan Analyst
Cost Allocation Agreement Cost Goods
Cost Goods Sold Cost Product Sold Ous
Cost Settlement Procedure 2009 Cost Sharing
Costs Costs Associated Exit Disposal Activities
Costs Awards Costs Ous Studies Utilized
Counterparts Counterparts Facsimile
Counterparts Integration Effectiveness Court Actions
Covenant Not Sue Amgen Agreement Covenant Triggering Event Certificate
Covenants Covenants Representation Warranties
Covered Employee Covered Termination
Creation Direct Financial Obligation Off-balance Sheet Arrangement Credit Agreement
Credits Account Critical Accounting Policies Estimates
Criticizing Sales Force Strategy Cumulative Effect Guidance Suggests Expect Finish 2009 Substantial
Cumulative Gross Margin Ous Cumulative Remedies
Curis Agreement Current Report Pursuant
Current Report Pursuant Securities Exchange Act 1934 Currently Not Manufacture Own Drug Products Candidates Able
Currently Not Manufacture Own Drug Products Some Candidates Damages Relief
Dan Mentioned Earlier Continue Work Better Understand Relationship Data Was Published Current Medical Research Opinion Found
Date 2005 Date 2006
Date 2007 Date Participation
Death Death Optionholder
Debarred Disqualified Persons Debt Issuance Costs
Decision Review Decisions
Default Payment Interest Due Payable Continues Period Calendar Defense
Deferral Agreement Deferral Contributions
Deferred Compensation Deferred Compensation Plan
Deferred Compensation Plans Defined Contribution 401 Plan
Defined Terms Definitions
Delay Omission Not Waiver Delays Conduct Completion Clinical Trials Analysis Data Manufacturing
Deliberation Then Amylin Shall Final Right Decide Facility Deliver Value Shareholders
Delivery Delivery Certain Information
Denial Claims Denominations
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Derivative Financial Instruments Designated Office
Designated Shares Designation Beneficiary
Designation Participants Detail Detailing
Detail Sample Reporting Determination Method Distribution
Development Development Activities
Development Budget Development Costs
Development Costs Exceeding Binding Budget Development Mrd
Development Plan Development Plan Through
Development Program Development Programs
Diabetes Diabetes Care
Diabetica Director Compensation
Directors Executive Officers Corporate Governance Directors Executive Officers Registrant
Disability Disability Optionholder
Discharge Liability Notes Disclaimer
Discretionary Bonus Discretionary Distributions
Discussions Between Parties Dispositions
Dispute Resolution Disputed Charges
Dissolution Liquidation Distribution Termination Plan
Distributions Dividend Rights Restrictions Transfer
Dividends Documentation
Documents Incorporated Reference Dont Let Icahn Eastbourne Throw Strategic Plan Off
Drug Approval Application Dtc
Due Authorization Duration Amendment Termination
Duration Program Update Duties
Each Following Conditions Precedent Before Disbursement Such Advance Early Exercise
Early Stage Programs Early Stage Strategic Collaborations
Early-stage Programs Research Earnings Conference Call
Eastbourne Capital Icahn Partners Publicly Indicated They Intend Eastham
Eberhard Effect Boards Decision
Effect Certain Corporate Events Effect Certain Events
Effect Supplemental Indentures Effective Date
Effective Date Plan Effective Time
Election Election Directors
Election Period Eli Lilly
Eligibility Eligibility Specific Stock Awards
Eligible Employee Eligible Option Recipients
Eligible Stock Award Recipients Elwood
Employee Employee Stock Ownership Plan
Employee Stock Purchase Plan Employees
Employer Employer Contributions
Employers Liability Employment Agreement
Employment Agreement Provisions Employment Agreements Arrangements
Employment Other Service Rights Employment Severance Change Control Agreements
Employment Succession Agreement Employment Taxes
English Language Enhance Stockholder Value
Entire Agreement Entire Agreement Amendment
Entire Agreement Amendments Entry Material Definitive Agreement
Entry Material Definitive Agreement 801 Other Events Environmental Laws
Equity Award Vesting Acceleration Benefits Equity Awards
Equity Compensation Plan Information Equity Incentive Compensation
Equity Incentive Plan Equity Incentives
Eqw Product Establishment Account
Establishment Trust Estimate Actual Manufacturing Costs
Estimated Eqw Manufacturing Initial Capital Investment Outside Facility Estimates
Event Default Event Elects
Events Default Events Requiring Distribution Benefits Participants Beneficiaries
Evidence Compliance Conditions Precedent Certificates Trustee Exact Name Registrant Specified Charter
Except Continuance Event Default Except Provided 1204 Adjustment Shall Dividends Shares Issued
Except Set Forth Below Undersigned Selling Securityholder Not Exchange Act
Exchange Information Exchange Lieu Conversion
Excluded Products Exclusions Binding Budgets
Exclusive Facility Utilization Fee Execution Authentication Delivery Dating
Execution Corporate Instruments Voting Securities Owned Corporation Execution Page
Execution Page Employers Copy Execution Page Fidelitys Copy
Executive Committee Executive Compensation
Executive Officer Executive Officers Directors Major Stockholders Control Approximately Common
Executive Summary Exenatide
Exenatide Clin Ical Data Analysis Shows Increased Risk Exenatide Injection
Exenatide Lar Exenatide Lar Manufacturing
Exenatide Once Weekly Exenatide Once Weekly Manufacturing
Exenatide Once Weekly Nda Submission Track End 2009 Exenatide Once Weekly Opportunity
Exenatide Once Weekly Pen Supply Agreement Exenatide Once Weekly Supply Agreement
Exercise Exercise Conversion Privilege
Exercise Price Exercise Price Payment
Exercise Right Terminate Exhaustion Remedies
Exhibits Existence
Existing Obligations Expanded Combination
Expect Gross Margins Remain Strong 2009 Approximately Explanatory
Export Exposed Potential Risks Legislation Requiring Companies Evaluate Internal
Exposed Potential Risks Recent Legislation Requiring Companies Evaluate Extension Termination Date
Facility Facility Adjusted Costs
Facility Payment Failure Comply Notice Requirements 1101 1201 Due
Fair Market Value Fair Value Measurements
Far Aware Meeting Saxagliptin Then Liraglutide Agenda Those Fdca
Federal Income Tax Information Feel Very Confident Regards Competitive Profile Byetta Course
Field Filing Authorization
Fill Date Finance Committee
Financial Operational Financial Results
Financial Results Fluctuate Fluctuations Cause Stock Price Fall Financial Statement Schedules
Financial Statements Exhibits Financial Statements Supplementary Data
Find Out Results Voting Annual Meeting Findings Validate Novel Integrated Neurohormonal Treatment Obesity Strategy
Firm Shares Foletta
Foletta Amylin Pharmaceuticals Inc Cfo Following Paragraph Quarter-end Financial Statements
Following Paragraph Year-end Financial Statements Force Majeure
Forecasts Foreign Currency Translation
Foreign Qualifications Forfeitures
Form 10-k Form Assignment
Form Compliance Certificate Form Designated Shares
Form Distribution Benefits Participants Beneficiaries Form Documents Delivered Trustee
Form Face Form Generally
Form Loan Notice Form Notice Conversion
Forward Looking Statements Fractions Shares
Fte Fundamental Principle Good Faith Fair Dealing
Furnish Trustee Names Addresses Holders Further Actions
Further Assurances Future Success Depends Ability Retain Chief Executive Officer
Future Success Depends Chief Executive Officer Other Key Future Success Depends Chief Executive Officer President Other
Gaap Gavin
General General Purpose
Generally Generation Amylinomimetic
Generation Amylinomimetic Davalintide Generic Product
Gergen Global Costs
Global Notes Good Morning Welcome Once Again Cowen 29th Annual
Governance Governance Activities
Governing Law Governing Law Jurisdiction Etc
Governing Plan Document Governing State Law
Government Regulation Governmental Approval
Graham Grant Purchase Rights Offering
Grantor Trust Grantors Remain Liable
Great Question Currently Over 1600 People Field Responsible Great Question Just Repeat Case Being Webcast Was
Greene Gregg
Gross Margin Ous Group
Gryphon Guess Other Part People Struggling Interested Comment Maintain
H-1 Had Response Agency Comment Since Liraglutide Panel Regard
Hazardous Materials Neither Nor Subsidiaries Undertaking Not Completed Head-to-head Duration-3 Study
Headings Held 2006
Hidden Defect Highlights
History Operating Losses Anticipate Future Never Become Profitable Hold Notes
Holder Householding Proxy Materials
However Ian Somaiya
Icahn Eastbourne Icahn Eastbourne Agenda Not Best Interests Shareholders
Icahn Eastbourne Suffer Fundamental Misunderstanding Amylins Business Immediate Release
Immediate Release 2006 Impairment
Impairment Charge Impairment Rights
Implemented Anti-takeover Provisions Discourage Prevent Acquisition Even Beneficial Implied Licenses
Implied Warranties Important
Important Information Important Safety Information
Important Safety Information Byetta Important Safety Information Byetta Exenatide Injection
In-license Agreement In-license Agreements
In-licensing Activities Inaudible Question Microphone Inaccessible Completed Within Next Few
Incentive Plan Incentive Stock Option
Incentive Stock Option 100000 Limitation Incentive Stock Option Nonstatutory
Incentive Stock Options Income Taxes
Inconsistent Obligations Incretin Mimetics
Ind Indebtedness
Indemnification Indemnification Amylin
Indemnification Electing Holders Agents Underwriters Indemnification Takeda
Indenture Indenture Shall Governed Construed Accordance Laws State New
Independence Board Directors Independence Board Directors Committees Corporate Governance
Independent Activities Independent Contractor Relationship
Independent Contractors Independent Registered Public Accountanting Firms Fees Services
Index Index Consolidated Financial Statements
Index Exhibits Indianapolis Ind San Diego Cal Usa 2006
Individual Accounts Information
Information Between Employer Trustee Information Regarding Audit Committee
Infringement Initial Grant
Initial Grants Initial Royalty Term
Initiation New Duration-5 Clinical Study Inspection Rejection
Insurance Integrated Neurohormonal Therapy Obesity
Integration Intellectual Property
Interest Other Income Expense Internal Control Integrated Framework
Interpretation Interpretation Construction
Introduction Invention
Inventories Inventories Net
Inventories Related Reserves Inventory Obsolescence
Investigation Failed Batch Investment Act
Investment Assurances Investment Decisions
Investment Options Investment Trust Funds
Investments Investments Marketable Debt Securities Subject Credit Market Risks
Investments Unconsolidated Entities Investors Security Holders Able Receive Proxy Statement Other
Invoice Invoices
Involuntary Termination Without Cause Issuance Common Stock
Issue Active Investigation Following Liraglutide Panel Number Things Jim Birchenough
Jim Birchenough Barclays Capital Analyst Jim Reddoch
Joint Inventions Joint Licenses
Joint Venture Journal Clinical Endocrinology Metabolism
Journal Title Current Medical Research Opinion Just Couple Questions Give Guys Still Anticipating Snda
Know Guess What Say Fda Past Put Products Knowledge
Kolterman Labeling Trademark
Last After They Issued Guidance Actually Connected Them Late-stage Development Programs
Latent Defect Launch Date
Lease Commitments Legal Holidays
Legal Proceedings Lenders
Leptin Less
Libor License
License Amylin License Development Commercialization Agreement
License Development Commercialization Agreement Dated 2009 Between Takeda License Takeda
Lilly Amylin Lilly Collaboration
Lilly Exenatide Collaboration Lilly Foreign Currency Conversion Methodology
Lilly Meetings Limitation
Limitation Liability Limitation Rights
Limitation Suits Limitations
Limitations Supply Litigation
Litigation Costs Litigation Regarding Patents Other Proprietary Rights Expensive Cause
Lloyd Loan Agreement
Loan Documents Loan Lilly Collateral Facility Built Ohio Manufacturing
Loan Party Required Registered Investment Act 1940 Loans Officers
Location Lock-up Letter
Long-range Plan Long-term
Long-term Payable Loss Impairment Investments
Loss Pramlintide Acetate Drug Substance Lot Numbering
Loyalty Maintenance Offices Agencies
Major Ous Market Make Change Adversely Affects Conversion Rights Notes
Make Change Provisions Require Each Holders Consent Waiver Make-whole Payment Debt Redemption
Mallinckrodt Inc Managements Report Internal Control Over Financial Reporting
Manager Managing Underwriters
Manner Investment Manufacture Manufacturing
Manufacture Product Manufacture Supply Licensed Compounds Products
Manufacturer Manufacturer Facilities
Manufacturer Inventions Manufacturers Technology
Manufacturing Manufacturing Information
Manufacturing Process Manufacturing Process License Technology Transfer
Marchetti Marketed Products
Marshall Matching Contributions
Material Activity Material Adverse Effect
Material Agreements Material Modification Rights Security Holders
Material Not Soliciting Deemed Filed Securities Exchange Incorporated Material Report Not Soliciting Deemed Filed Sec Incorporated
Material Report Not Soliciting Deemed Filed Securities Exchange Materials
Materials Transfer Matt Osborne
Maturity Date Maximize Exenatide Once Weekly Opportunity
Maximum Potential Bonus Medical Inquires
Medical Sales Representative Meetings
Meetings Board Directors Committee Member Attendance Meg Malloy
Merger Conversion Consolidation Succession Business Method Payment
Method Payment Currency Method Timing Distributions
Metreleptin Michael York Amylin Pharmaceuticals Inc Senior Director
Mike King Minimum Exercise Price Option
Minimum Orders Miscellaneous
Miscellaneous Provisions Mischaracterizing Interactions
Mitigation Damages Modifications
Money Held Trust Money Payments Held Trust
Mrd Mutilated Destroyed Lost Stolen Notes
Name Publicity Names Addresses Representatives
Nasal Exenatide Nasd
Nasd Rules Nda
Negatively Affected Result Proxy Fight Other Actions Activist Negatively Affected Result Threatened Proxy Fight Other Actions
Net Loss Net Loss Per Share
Net Loss Was 478 034 Per Share Compared Net Product Sales
Net Product Sales Increase Net Product Sales Increase 162
Net Product Sales Increase ~22 Full Commercialization Net Product Sales Increased Over 2006 167
Net Product Sales Increased Over 2006 177 Net Product Sales Increased Over 2006 701
Net Product Sales Increased Over 2007 7653 Positive Net Product Sales Increased Over Prior 109
Net Product Sales Increased Over Prior 139 Net Sales
New Drug Application Exenatide Once Weekly Submitted Accepted New York Business
Nominate Candidate Director Nominating Governance Committee
Nominees Blue Proxy Card Today Non-bid Products
Non-bid Study Non-competition
Non-duplication Benefits Non-employee Director
Non-employee Director Option Non-exclusive
Non-major Ous Markets Non-solicitation
Non-waiver Nonalienability Benefits
Nondiscriminatory Exercise Authority Nonstatutory Stock Option
Nonstatutory Stock Options Restricted Awards Normal Early Retirement
Not Applicable Not Approvable Letter Received Symlin Basal Insulin Alone
Not Debarred Not Manufacture Own Drug Candidates Able Obtain Adequate
Not Manufacture Own Drug Products Candidates Able Obtain Not Required Qualify Foreign Corporation General Consent Service
Not Responsible Recitals Issuance Notes Notes
Notice Notice Adjustments Conversion Rate
Notice Amylins 2008 Annual Stockholder Meeting Proxy Statement Notice Annual Meeting Stockholders Held 2007
Notice Annual Meeting Stockholders Held 2008 Notice Defaults
Notice Holders Waiver Notice Questionnaire
Notice Supplemental Indentures Notice Transfer Pursuant Registration Statement
Notice Trustee Notices
Notices Claims Etc Notices Etc Trustee
Novaquest Detail Now Highlight Progress Areas Mentioned Earlier Byetta Only
Now Provide Brief Overview Current Business Noted Earlier Now Therefore
Now Therefore Indenture Witnesseth Now Turn Call Over Dan Bradbury
Number 0-19700 Number Shares Exercise Price
Obesity Obesity Commercialization Committee
Obesity Development Committee Obesity Program
Obesity Programs Obesity Steering Committee
Objective Obligations
Occ Oct 2009
Off-balance Sheet Arrangements Offering
Offerings Officer
Officer Means Officers
Officers Certificate Opinion Counsel Offices
Offset Indebtedness Only Plan Sell Wrong Time
Operation Opinion Report Notice Request Direction Consent Order Bond
Option Option Agreement
Option Compounds Option Exercise
Option Grant Practices Option Not Service Contract
Option Provisions Optional Shares
Optionholder Organization
Organization Standing Orville Dont Know Add Additional Thoughts
Other Amylin Agreements Other Collaborations
Other Commitments Other Compensation
Other Contributions Other Costs
Other Current Assets Other Current Liabilities
Other Elements Compensation Other Employer Contributions
Other Events Other Income Expense
Other Information Other Material Indebtedness
Other Matters Other Opportunity Pipeline Second-generation Amylin Mimic Called Davalintide
Other Plan Terminations Other Registration Rights
Other Securities Corporation Other Takeda Agreement
Other Termination Employment Ous Bid Commercialization Trial Costs
Ous Bid Development Trial Costs Ous Commercialization Activities
Ous Costs Ous Non-bid Commercialization Trial Costs
Ous Non-bid Development Trial Costs Ous Pen Product Purchase Price
Ous Royalties Outside Director
Over 500 Total Revenue Reported 2006 Over Past Several Corporate Governance Committee Close Consultation
Over-allotment Option Overall Prescriptions Symlin Declined Approximately Although New Innovative
Overview P-lly
Pacira Agreement Parachute Payments
Participant Participant Contributions
Participants 401 Plan Participants 401 Plan Esop
Participants Solicitation Participation
Participation Plan Participation Withdrawal Termination
Parties Interest Party
Party Beneficiaries Party Development Costs
Party Standstill Provisions Party Supplier
Party Suppliers Patents
Patents Determined Unenforceable Unable Obtain New Based Current Patents Proprietary Rights Licenses
Payable Paying Proxy Solicitation
Payment Payment Commencement Date
Payment Election Overrides Payment Interest Rights Preserved
Payment Principal Interest Payment Purchase Price Payroll Deductions
Pde Reimbursement Pen Product
Pen Product Capital Investments Pen Product Cost
Pen Product Initial Capital Investment Pen Product Manufacturing Development Costs
Pen Product Specifications Per Share Data
Percent Patients Achieved A1c Treatment Goal Percent Stockholder
Percent Stockholders Performance Measurement Comparison
Performance Standards Period
Periods Permissible Delays Payment
Permitted Acceleration Payment Perquisites
Perquisites Certain Benefits Person
Person Rights Persons Deemed Owners
Pharmacovigilance Phase Clinical Trial
Phase Dose-ranging Study Complete Phase Programs
Phil Nadeau Plan
Plan Administration Change Control Plan Administrative Costs
Plan Benefits Plan Matching Contribution
Plan Number Plan Sponsor
Plan Suspension Plan Term
Plan Termination Following Change Control Corporate Dissolution Please Sec Deem Short Sales Securities Covered Registration
Please Sec Requires Natural Persons Named Prospectus Please Vote Date Promptly Return Proxy Enclosed Envelope
Pledge Security Agreement Point Unexpected New Byetta Label Address Class Effect
Position Detail Post-approval Clinical Trials
Potential Limitation Deductions Potential Modest Downside Associated Working Capital Investments Choose
Power Authority Powers Board
Powers Responsibilities Administrator Pramlintide
Pramlintide Acetate Pramlintide Metreleptin
Pramlintide-metreleptin Combination Product Candidate Pre-approval Policies Procedures
Preamble Preferential Collection Claims Against
Preliminary 2005 Results Prescription Vouchers
Preservation Information Price Increases Over Last Few Been Reasonably Aggressive
Pricing Pricing Agreement
Primary Detail Equivalent Principal Accountant Fees Services
Principles Consolidation Priority Product
Pro-forma Information Sfas 123 Periods Prior 2006 Procedures Termination Material Breach
Proceeds Shares Common Stock Proceeds Stock
Product Product Liabilities
Product Liability Insurance Product Pipeline Programs
Product Price Product Returns
Product Sales Increased Over 2007 200 Product Sales Increased Over 2007 201
Product Sample Product Sample Costs
Product Warranties Profit Loss Share
Prohibited Investments Promissory
Promotion President Coo Election Board Promotional Materials Samples
Properties Property Equipment
Property Plant Equipment Prosecution
Prospectus Provide Conversion Notes Pursuant 1210
Provided Provided However
Provision Case Effect Reclassification Consolidation Merger Sale Provisions Restricted Stock Awards
Proxy Solicited Board Directors Annual Meeting Stockholders Held Psylin Agreement
Public Offering Common Stock Public Offerings Common Stock
Publicity Purchase Agreement
Purchase Components Purchase Date
Purchase Orders Purchase Pen Product Requirements
Purchase Period Purchase Price
Purchase Price Adjustment Purchase Right
Purchase Rights Price Purchase Specifications Pramlintide Acetate Injection Cartridges
Purchase Stock Purchase Supply Agreement
Purchasers Purpose
Purposes Relationship 2003 Non-employee Directors Stock Option Plan Pursuant 103 Following Employees Eligible Participate Plan
Pyy 3-36 Quality Agreement
Quality Governance Quantitative Qualitative Disclosures Market Risk
Question Answer Breakout Questionnaire
Ratification Selection Independent Auditors Rebates Wholesaler Chargebacks
Recalls Recalls Product Quality Safety
Recalls Similar Actions Receiving Proxy Materials
Recent Fda Advisory Committee Meeting Concern Was Raised Recently Issued Accounting Pronouncements
Recently Issued Accounting Standards Recitals
Reclassifications Records
Records Disclosure Data Results Records Product Sales Following Launch First-in-class Diabetes Medicines
Redemption Convertible Senior Notes Regarding Internet Voting
Regarding Non-gaap Financial Measures Regards Duration-5 Being Undertaken Number Reasons Also Important
Registrable Securities Registration Expenses
Registration Rights Registration Statement
Regulatory Approval Regulatory Approval Clinical Trials
Regulatory Authority Regulatory Inspections
Regulatory Lead Regulatory Materials
Regulatory Matters Regulatory Responsibility
Reimbursement Agreement Reimbursement Costs Incurred
Reinstatement Related Corporation
Relationship 2001 Equity Incentive Plan Relationship 2003 Non-employee Directors Stock Option Plan
Release Release Deemed Solicitation Material Respect Matters Considered 2009
Release Termination Release Testing
Release Waiver Claims Relevant Corporations
Remain Committed Optimizing Potential Only Type Diabetes Medicine Remainder Page Intentionally Left Blank
Remedies Remedies Default
Report Adjustment Report Audit Committee Board
Report Audit Committee Board Directors Report Compensation Committee Board Directors Executive
Report Independent Registered Public Accounting Firm Reporting
Reporting Comprehensive Income Reporting Gross Revenue Principal Net Agent
Reports Representations Warranties
Representations Warranties Lilly Representatives
Request Review Require Additional Financing Future Not Available Favorable Terms
Require Future Capital Uncertain Availability Terms Additional Funding Required Delay Payment Key Employees
Required Redeem Convertible Senior Notes Designated Event Required Redeem Convertible Senior Notes Designated Event Repay
Required Redeem Convertible Senior Notes Due 2011 Designated Research Activities
Research Development Activities Planned Manufacturing Involve Hazardous Materials Research Development Expenses
Research Development Programs Fail Result Additional Drug Candidates Reservation Rights Amylin
Reservation Rights Takeda Reserve Common Stock
Resignation Removal Appointment Successor Resolution Senior Executives
Responsibilities Responsibility Development Costs
Responsibility Trustee Conversion Provisions Rest World
Restoration Rights Remedies Restricted Payments
Restricted Security Restricted Stock Awards
Restriction Limitation Liability Restrictions Transfer
Restructuring Restructuring Exenatide Operations Lilly
Results Conference Call Scheduled Results Operations Financial Condition
Resumption Participation Following Reemployment Retroactive Amendments
Return Funds Excess Fundamental Change Repurchase Price Revenue Collaborative Agreements
Revenue Recognition Revenues Collaborative Agreements
Reversion Rights Reversion Shares Share Reserve
Review Components Executive Compensation Revolving Loans Payments Respect Thereto
Right Cross-reference Right Require Repurchase Fundamental Change
Rights Remedies Cumulative Rights Stockholder
Risk Risk Factors Cautionary Affect Future Results
Riskmetrics Splits Recommendation Proxy Contest Rowland
Rule 16b-3 Rules Procedures
Rules Regulations Sab 108
Safe Harbor Forward Looking Statements Safe Harbor Statement
Safety Stock Salary
Salary Continuation Payments Sales Distribution
Sales Marketing Distribution Sales-based Milestones
Same Degree Care Skill Exercise Prudent Person Circumstances Sample
San Diego San Diego Calif Indianapolis Ind
San Diego Calif Indianapolis Ind Cambridge Mass 2009 San Diego California 92121
San Diego Indianapolis 2006 San Diego Indianapolis 2007
San Diego Indianapolis 2008 San Diego Indianapolis Cambridge
San Diego Indianapolis Cambridge 2005 San Diego Indianapolis Cambridge 2007-
San Diego Indianapolis Cambridge 2009 San Diego Oct 2007
Say View Patents Whilst Believe Extremely Important Also Schedule
Schedule 14a Schedule Form Payment
Scope Rule Lillys Person Plant Scriveners Error
Scwt Meet Such Other Times Agreed Parties Less Sec-registered Money Market Funds
Secondary Royalty Term Secure
Secure Amylins Future Potential Exenatide Once Weekly Vote Secure Amylins Future Potential Exenatide Once Weekly- Vote
Securities Account Control Agreements Mortgage Securities Act Etc
Securities Exchange Act 1934 Securities Law Compliance
Securities Registered Pursuant Act Security Interest Absolute
Security Ownership Certain Beneficial Owners Management Related Shareholder See
See Continuing Very Focused Managing Expenses Indeed Cash See Looking Cadre Studies Positioning Exenatide Once Weekly
Select Selling General Administrative Expenses
Selling General Administrative Expenses Decreased 876 Compared 982 Separate Account
Separation Service Service
Settlement Settlement Existing Cross-charging Corrections Procedure Future
Severability Share Reserve
Share-based Payment Shareholder Rights Plan
Shares Shares Common Stock Subject Plan
Shares Reserved Future Issuance Shares Stock
Shares Subject Plan Shelf Registration
Shelf Registration Statement Shipment Delivery
Shipping Handling Costs Short-term Investment
Short-term Investments Signature
Signature Page Follow Signature Page Follows
Signature Pages Follow Signatures
Significant Amount Indebtedness Not Able Make Payments Incur Single Lot Ous
Sitagliptin Pioglitazone Skyler
Source Shares Special Acceleration Provisions
Specific Performance Specifications
Standard Cost Statement Officers Default
Stetsko Steve Harr
Stock Award Stock Award Agreement
Stock Investment Options Stock Option
Stock Option Agreement Nonstatutory Stock Option Grants Exercises
Stock Option Plans Stock Ownership
Stock Ownership Guidelines Stock Purchase Plans
Stock Subject 2001 Eip Stock Subject 2001 Espp
Stock Subject 2001 Purchase Plan Stock Subject Incentive Plan
Stock Warrants Stock-based Compensation Information Sfas 123r
Stockholder Approval Stockholder Communications Board Directors
Stockholder Proposals Due Next Annual Meeting Stockholder Record Shares Registered Name
Stockholder Rights Stockholders Equity
Strategic Relationships Strategic Restructuring Workforce Reduction
Study Design Study Details
Study Finally Finalize Obesity Funding Development Strategy Includes Subcommittees
Subcontracting Subject Fraud Abuse Similar Laws Regulations Failure Comply
Sublicensing Submission Matters Vote Security Holders
Subsections Agreement Hereby Amended Restated Entirety Follows Subsequent Event
Subsequent Events Subsidiaries Amylin Pharmaceuticals Inc
Subsidiaries Taken Whole Ability Consummate Transactions Contemplated Herein Substantial Future Sales Common Stock Existing Stockholders Conversion
Substantial Risk Forfeiture Lapse Date Substantially Dependent Collaboration Lilly Development Commercialization Byetta Alkermes
Successor Substituted Successors
Successors Assigns Sullivan
Summary Description Named Executive Officer Oral At-will Employment Superior Glucose Control Weight Loss Less Hypoglycemia Compared
Supplemental Indentures Consent Holders Notes Supplemental Indentures Without Consent Holders Notes
Supplemental New Drug Application Byetta Submitted Fda Tzds Supply Agreement
Supply Chain Working Team Supply Following Termination
Sure Measuring Clinically Exenatide Lar Been Since Baseline Surrendered Without Charge Such Holder New Notes Authorized
Survival Agreement Survival Certain Provisions
Survival Termination Surviving Terms
Symlin Symlin Development Activities
Symlin Manufacturing Symlin Pramlintide Acetate Injection
Table Contents Takeda Acknowledgment
Takeda Know-how Takeda Licensed Compound
Takeda Obesity Collaboration Takeda Patents
Takeda Pharmaceutical Limited Takeda Y-family Agonists
Takeda Y-family Agonists Nominated Compounds Tax Withholding
Taxes Taxes Conversions
Term Term Agreement
Term Loans Payments Respect Thereto Term Termination
Termination Termination Benefits
Termination Cause Termination Change Control
Termination Continuous Service Termination Continuous Service Due Retirement
Termination Either Party Termination Employment
Termination Material Definitive Agreement Termination Participants Continuous Service
Termination Participation Termination Suspension Plan
Terms Options Terms Specific Additional Action Orville Just Indicated Responding
Testman Thanks Dan Very Helpful
Then Also Just Wanted Check Actually Had Chance Then Another Question Comparability Results Expect Those Presented
Then Finally Last Sort Housekeeping Question Had Mentioned Then Was Also Hoping Comment What Regulatory Submissions
They Distinct They Not Actually Counted Biologics Reviewed Cder Cber
Think Refer Back Collaboration Agreement Change Control Provision Think What Ask Orville Comment Question Was Actually
Thomas Wei Through Ongoing Interactions Agency Continue Believe Duration-1 Study
Time Delivery Time Distribution
Time Making Contributions Time Payments Shall Essence
Time Sale Prospectus Timing Distributions
Timing Election Defer Title
Title Terms Title Transfer Shipment Pen Product
Today Elect Amylins Highly-qualified Nominees Together Collaboration Partners Lilly Alkermes Pleased Exenatide Once
Total Revenue Was 1937 Including Net Product Sales Towne Centre Drive
Towne Centre Drive San Diego California 92121 Trade Dress Packaging
Trading Training Related Amylin Sales Force Issues
Transferability Transferability Incentive Stock Option
Transferability Nonstatutory Stock Option Transferability Stock Awards Value Consideration
Transition Ceo Position Treatment Obesity Pramlintide
Treatment Rights True-up
Trust Indenture Act Trustee Enforce Claims Without Possession Notes
Trustee Proofs Claim Trustee Shall Cease Eligible 609 Fail Resign After
Trustee Sign Amendments Etc Trustee Take Other Action Deemed Proper Not Inconsistent
Unable Adequately Prevent Disclosure Trade Secrets Other Proprietary Unable Obtain Regulatory Clearance Market Drug Candidates Including
Unable Obtain Regulatory Clearance Market Drug Candidates United Unconditional Right Holders Receive Principal Interest Convert
Undertaking Costs Underwriters
Underwriting Agreement Underwritten Offering
Unforeseeable Emergency Unforeseeable Emergency Withdrawals
Unidentified Participant United States
Unless Unless Contrary Direction Indicated Proxy Voted Nominees Listed
Unregistered Sales Equity Securities Unsecured General Creditor Employer
Upfront Fee Urge Act Now Vote Blue Proxy Card
Urgent Immediate Attention Requested Urges Shareholders Support Boards Strategy Vote Blue Proxy
Valid Claim Validity
Valuation Stock-based Compensation Vesting
Vesting Generally Vice President Finance Chief Financial Officer
Vince Mihalik Amylin Pharmaceuticals Inc Svp Sales Marketing Vivo
Vote Vote Annual Meeting
Vote Boards Superior Nominees Blue Proxy Card Today Vote Important Matter Few Shares Own
Votes Votes Counted
Votes Needed Approve Each Proposal Waiver
Waiver Acknowledgment Waiver Jury Trial
Waiver Modification Agreement Waiver Past Defaults
Waiver Rule Construction Waiver Stay Usury Extension Laws
Waiver Subrogation Waivers
Webcast Investor Conference Call Welcome
Well Think What Going Number Things Being Looked What Mean Receive Proxy Card
What Quorum Requirement What Return Proxy Card Not Make Specific Choices
What Voting Whereas
While Process Taken Considerable Time Continue Encouraged Interactions Wholesaler Discounts
Wilson Winding Down Activities
Withdrawal Withholding Obligations
Within Fifteen After Receipt Proposed Product Development Plan Without Limiting Foregoing Adjustment Conversion Rate Need
Witness Witness Whereof
Witness Whereof Amylin Pharmaceuticals Inc 2001 Non-qualified Deferred Wwwamylincom
Wwwproxyvotecom X7272
Yes 165 Young
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki